Present initial single-ascending dose data from the phase 1 study of DISC-3405
Delivered by the deadline
AI-confirmed · human review in progress Independent AI checks agreed on primary SEC or regulator evidence. Records are now being reviewed by hand, starting with those our customers order.
- Announced
- 9 May 2024
- Due
- 30 Jun 2024
- Delivered
- June 2024
- Deadline
- Met
- Late
- Not met
- Today
What the company said
“initial single-ascending dose (SAD) data from the phase 1 study of DISC-3405 in healthy volunteers in Q2 2024”
What we found
Evidence strength A What the grades mean
The company presented interim single-ascending dose (SAD) data from the Phase 1 study of DISC-3405 in June 2024, meeting the Q2 2024 deadline.
-
A Disc Medicine, Inc. 10-Q filed 2024-08-08
“Interim data was presented from the single-ascending dose (SAD) portion of the Phase 1 clinical trial of DISC-3405 in healthy volunteers in June 2024.” ✓ confirmed on the page
Market reaction: the shares moved +6.3% against the S&P 500 over the three sessions around the disclosure (7 Aug 2024 to 12 Aug 2024). What this measures
Checked 1 Oct 2026.
Commitment lineage
Every time the company restated this commitment. The original is never changed, and the outcome is always measured against version 1.
- Deadline drift +914 days
- 2 versions
-
Version 1 · original · stated 9 May 2024
Deadline 30 Jun 2024 (“Q2 2024”)
-
Version 2 · stated 6 Nov 2025
Deadline 31 Dec 2026 (“2026”) · wording expected
“Progressing ongoing Phase 2 study of DISC-3405 in patients with PV with initial data expected in 2026”
Commitment DNA
The structured record of this commitment. Fields the company did not state are left blank rather than guessed.
- Event type
- Clinical readout
- Indicative materiality
- Medium rules
- Action
- Present
- Deliverable
- DISC-3405 phase 1 SAD data
- In the company’s control
- High
- Specificity
- High
How this entry was checked
- Commitment recordedThe company's words were matched word for word against the filing.
- First checkAn AI model, Gemini (Google), read the company's later filings and recorded the outcome with a quoted passage.
- Second check: agreesA different AI model, Claude (Anthropic), re-read the evidence without being told the outcome and reached the same answer.
Confirmed. This outcome counts towards the company's Kept Score. How verification works
Are you Disc Medicine, Inc.? You can publish an official statement next to this entry, free. Add a statement.
Is something here wrong or out of date? Companies and readers can ask us to check it. Please bring a link to a public source.
Report an error in this entry Reference: KI-C-2024-IRON-002164 · Corrections policy